BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne

Reuters

15 Jun

BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne

June 15 (Reuters) - Sarepta Therapeutics Inc SRPT.O:

SAREPTA PROVIDES SAFETY UPDATE FOR ELEVIDYS AND INITIATES STEPS TO STRENGTHEN SAFETY IN NON-AMBULATORY INDIVIDUALS WITH DUCHENNE
SAREPTA THERAPEUTICS INC - SECOND CASE OF ACUTE LIVER FAILURE RESULTING IN DEATH REPORTED
SAREPTA THERAPEUTICS INC - SHIPMENTS OF ELEVIDYS FOR NON-AMBULATORY PATIENTS SUSPENDED
SAREPTA THERAPEUTICS INC - ENVISION STUDY PAUSED FOR PROTOCOL AMENDMENT
SAREPTA THERAPEUTICS INC - FDA CONCURS WITH PAUSE IN ENVISION STUDY DOSING
SAREPTA THERAPEUTICS INC - EVENT REPORTED TO FDA AND GLOBAL HEALTH AUTHORITIES

Source text: ID:nBw2qK9rQa

Further company coverage: SRPT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2543018699"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543018699\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543018699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-15 13:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543018699","market":"nz","top_or_hot":-1,"title":"BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne</title></head><body><p><span>June 15 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> Inc <span>SRPT.O</span>:</p><ul><li><p>SAREPTA PROVIDES SAFETY UPDATE FOR ELEVIDYS AND INITIATES STEPS TO STRENGTHEN SAFETY IN NON-AMBULATORY INDIVIDUALS WITH DUCHENNE</p></li><li><p>SAREPTA THERAPEUTICS INC - SECOND CASE OF ACUTE LIVER FAILURE RESULTING IN DEATH REPORTED</p></li><li><p>SAREPTA THERAPEUTICS INC - SHIPMENTS OF ELEVIDYS FOR NON-AMBULATORY PATIENTS SUSPENDED</p></li><li><p>SAREPTA THERAPEUTICS INC - ENVISION STUDY PAUSED FOR PROTOCOL AMENDMENT</p></li><li><p>SAREPTA THERAPEUTICS INC - FDA CONCURS WITH PAUSE IN ENVISION STUDY DOSING</p></li><li><p>SAREPTA THERAPEUTICS INC - EVENT REPORTED TO FDA AND GLOBAL HEALTH AUTHORITIES</p></li></ul><p>Source text: <span>ID:nBw2qK9rQa</span></p><p>Further company coverage: <span>SRPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-15 13:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne</title></head><body><p><span>June 15 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> Inc <span>SRPT.O</span>:</p><ul><li><p>SAREPTA PROVIDES SAFETY UPDATE FOR ELEVIDYS AND INITIATES STEPS TO STRENGTHEN SAFETY IN NON-AMBULATORY INDIVIDUALS WITH DUCHENNE</p></li><li><p>SAREPTA THERAPEUTICS INC - SECOND CASE OF ACUTE LIVER FAILURE RESULTING IN DEATH REPORTED</p></li><li><p>SAREPTA THERAPEUTICS INC - SHIPMENTS OF ELEVIDYS FOR NON-AMBULATORY PATIENTS SUSPENDED</p></li><li><p>SAREPTA THERAPEUTICS INC - ENVISION STUDY PAUSED FOR PROTOCOL AMENDMENT</p></li><li><p>SAREPTA THERAPEUTICS INC - FDA CONCURS WITH PAUSE IN ENVISION STUDY DOSING</p></li><li><p>SAREPTA THERAPEUTICS INC - EVENT REPORTED TO FDA AND GLOBAL HEALTH AUTHORITIES</p></li></ul><p>Source text: <span>ID:nBw2qK9rQa</span></p><p>Further company coverage: <span>SRPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250615:nTUA701YFW:1","article_id":"2543018699","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543018699","pubTimestamp":1749964800,"columns":[{"name":"Earnings Express","id":26,"label_key":"express"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With DuchenneJune 15 (Reuters) - Sarepta Therapeutics Inc SRPT.O:SAREPTA PROVID","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"简介-Sarepta提供Elevidys的安全性更新，并采取措施加强非流动杜兴氏病患者的安全性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9},"content_text":"BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With DuchenneJune 15 (Reuters) - Sarepta Therapeutics Inc SRPT.O:SAREPTA PROVIDES SAFETY UPDATE FOR ELEVIDYS AND INITIATES STEPS TO STRENGTHEN SAFETY IN NON-AMBULATORY INDIVIDUALS WITH DUCHENNESAREPTA THERAPEUTICS INC - SECOND CASE OF ACUTE LIVER FAILURE RESULTING IN DEATH REPORTEDSAREPTA THERAPEUTICS INC - SHIPMENTS OF ELEVIDYS FOR NON-AMBULATORY PATIENTS SUSPENDEDSAREPTA THERAPEUTICS INC - ENVISION STUDY PAUSED FOR PROTOCOL AMENDMENTSAREPTA THERAPEUTICS INC - FDA CONCURS WITH PAUSE IN ENVISION STUDY DOSINGSAREPTA THERAPEUTICS INC - EVENT REPORTED TO FDA AND GLOBAL HEALTH AUTHORITIESSource text: ID:nBw2qK9rQaFurther company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}